For appropriate patients with type 2 diabetes...
Start with the power of JANUMET
In a study of patients uncontrolled with diet and exercise at 24 weeks, JANUMET delivered powerful A1C reductions, got nearly twice as many patients to goal, and provided significantly greater reductions in both PPG and FPG vs metformin alone.1
Data in Higher Baseline A1C Patients (median baseline A1C=9.7%)
In a study of patients uncontrolled with diet and exercise at 18 weeks, JANUMET delivered powerful A1C reductions, with nearly 1 in 2 patients achieving ADA goal and significantly greater reductions in FPG vs metformin alone.2
JANUMET is contraindicated in patients with renal disease or renal dysfunction (serum creatinine levels >1.5 mg/dL in males and >1.4 mg/dL in females) or abnormal creatinine clearance; acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma; or history of a serious hypersensitivity reaction to JANUMET or sitagliptin (one of the components of JANUMET), such as anaphylaxis or angioedema.
Temporarily discontinue JANUMET in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such products may result in acute alteration of renal function. Avoid use in patients with hepatic disease. Temporarily discontinue for intercurrent serious conditions, infection, or surgery.